Deal

MediSapiens received funding for groundbreaking cancer medicine software

MediSapiens has received USD 1 million for the world’s first personalized cancer medicine software.  

MediSapiens, world’s first software company for personalized cancer medicine in oncology clinics and drug development, completed USD 1 million round investment from ETFIII advised by Eqvitec Partners, Veraventure, VTT Ventures and Lifeline Ventures.

MediSapiens is based on scientific research at the VTT Technical Research Centre of Finland and its collaborators. MediSapiens hosts world’s largest unified gene expression database of human tissues and diseases. This enables scientists to understand the role of human genes in health and disease – to be applied in helping oncologists in choosing optimal treatments and biopharmaceutical companies in developing next generation personalized medicines.

Read more


FundVerdane ETF III SPV (PKA Eqvitec Technology Fund III) Argentum share 14.19%
Portfolio CompanyMediSapiens
Date of Transaction2010-06-01
TransactionAcquisition
Seller
Buyer
Size of TransactionUSD 100.0m
Ind. FocusLife Science
GeographyFinland
StageVenture
 

More deals